CJC-1295 Without DAC – Research Peptide for Laboratory Studies

CJC-1295 Without DAC, also referred to as Modified GRF 1-29 (Mod GRF 1-29), is a synthetic peptide studied in research involving growth hormone-releasing hormone (GHRH) signaling, peptide pharmacology, and the regulation of the GH/IGF-1 pathway. Unlike the long-acting CJC-1295 formulation containing the Drug Affinity Complex (DAC), CJC-1295 Without DAC is designed as a shorter-acting research analog. This distinction makes it particularly relevant for laboratory investigations comparing peptide structure, pharmacokinetics, receptor activity, and growth-hormone-related signaling.

CJC-1295 Without DAC Research Overview

CJC-1295 is related to the GHRH(1-29) peptide family and has been investigated for its effects on growth hormone and IGF-1 secretion. Human research on the parent CJC-1295 compound has demonstrated changes in GH and IGF-1 concentrations following administration. However, these findings should not automatically be interpreted as evidence for equivalent clinical effects from CJC-1295 Without DAC. For researchers investigating peptide signaling, CJC-1295 Without DAC can be considered within broader studies involving:

• GHRH receptor signaling
• Growth hormone secretion pathways
• GH/IGF-1 axis research
• Peptide structure and stability
• Comparative peptide pharmacology
• Short-acting versus long-acting GHRH analogs
• Laboratory studies of endocrine signaling

Researchers interested in related compounds can also explore our [GHRP-2 Acetate], [HGH 191AA], and [ARA-290] research products.

CJC-1295 Without DAC vs. CJC-1295 With DAC

The primary distinction researchers examine is the presence or absence of the Drug Affinity Complex. CJC-1295 with DAC was developed as a long-acting GHRH analog. Published human studies found sustained increases in GH and IGF-1 following administration of CJC-1295, with effects persisting for days. CJC-1295 Without DAC, commonly associated with Modified GRF 1-29, lacks the albumin-binding DAC component and is therefore studied as a shorter-acting peptide. Current reviews emphasize that direct controlled human research specifically evaluating the no-DAC form remains limited. This difference makes the two forms useful subjects for comparative laboratory research involving peptide duration, pharmacokinetics, and signaling characteristics.

Scientific Research and GH/IGF-1 Signaling

GHRH plays an important role in regulating pituitary growth hormone secretion. Research into CJC-1295 has helped investigate how modified GHRH analogs interact with this physiological pathway. A randomized controlled study published in the Journal of Clinical Endocrinology & Metabolism investigated CJC-1295 in healthy adults and reported dose-dependent increases in circulating GH and IGF-1 concentrations. Another human study examined GH pulsatility following CJC-1295 administration and reported increased GH secretion while pulsatile secretion was maintained. For researchers reviewing the underlying literature, these studies provide useful background when examining the broader pharmacology of GHRH analogs.

Related Research Peptides

Researchers exploring CJC-1295 Without DAC may also be interested in related peptide research categories available through our catalog:

• [Modified GRF 1-29 + Ipamorelin]
• [GHRP-2 Acetate]
• [Adipotide]
• [AOD-9604]
• [BPC-157 / TB-500 / GHK-Cu Blend]
• [Gonadorelin Acetate]

For additional research compounds, visit our [research peptide collection].

External Scientific References

Researchers can review the published literature through authoritative scientific databases:

• PubMed – CJC-1295 and GH/IGF-1 Research
• PubMed – CJC-1295 and Growth Hormone Pulsatility
• PubMed – GHRH(1-29) and CJC-1295 Research
• PMC – Recent Review of GH/IGF-1 Modulating Peptides

Research-Use Disclaimer

CJC-1295 Without DAC is provided for research and laboratory purposes only. It is not intended for human consumption, self-administration, diagnosis, treatment, prevention, or mitigation of any disease or medical condition. Research findings involving related CJC-1295 compounds should not be presented as proof of clinical efficacy for CJC-1295 Without DAC. Researchers should independently evaluate the available scientific literature, regulatory requirements, product documentation, and appropriate laboratory safety procedures. CJC-1295 Without DAC – research-focused peptide material for qualified laboratory investigations and scientific study.